Type 1 Diabetes Mellitus in the First Years of Life - Onset, Initial Treatment, and Early Disease Course

J Ziegler1, S R Tittel2,3, T Biester4

  • 1University Hospital Tübingen, Department of Pediatric and Adolescent Medicine, Tübingen, Germany.

Insights

Type 1 diabetes (T1D) in young children presents with higher diabetic ketoacidosis (DKA) rates but is effectively managed with insulin pump therapy. Glycemic control remains similar across age groups, with no increased risk of severe hypoglycemia or DKA.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Type 1 diabetes (T1D) onset in early childhood presents unique challenges.
  • Understanding treatment patterns and outcomes in very young children with T1D is crucial for optimizing care.

Purpose of the Study:

  • To investigate the onset characteristics and treatment choices for T1D in children under four years of age.
  • To compare clinical status, treatment modalities, and glycemic control across different age-at-onset groups.

Main Methods:

  • Analysis of 5,763 patients from the German Diabetes Patient Follow-up registry with T1D onset between 6-48 months.
  • Comparison of three groups based on age at onset: 6-<12 months, 12-<24 months, and 24-48 months.
  • Evaluation of diabetes-specific parameters, anthropometrics, and treatment modes (CSII, MDI, CGM) at onset and during the first two years.

Main Results:

  • Children with T1D onset under 4 years experienced higher rates of diabetic ketoacidosis (DKA) at diagnosis compared to older children (up to 52.3% vs. 27.3%).
  • Insulin pump therapy (CSII) was the predominant treatment 2 years post-onset for younger children (94.1%-98.1%) compared to older children (85.8%).
  • Median HbA1c levels after 2 years were similar across all groups (<7.5%), with no significant difference in severe hypoglycemia (SH) or DKA rates during the first two years of treatment.

Conclusions:

  • Very early onset T1D (under 4 years) is associated with a higher incidence of DKA at diagnosis.
  • Insulin pump therapy is widely adopted for young children with T1D, achieving comparable glycemic control (HbA1c) to older children without increasing severe hypoglycemia or DKA risks.
  • Continuous glucose monitoring (CGM) use did not show an association with lower HbA1c in children under 48 months.
Abstract

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
910
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
246
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
161